Adult Clinical Trials

Brain Cancer

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact 919.684.5301 or visit The Preston Robert Tisch Brain Tumor Center at Duke.

18 trials identified.

In-Vitro Generation and Characterization of Cytotoxic T Lymphocytes (CTL) Using Dendritic Cells From Malignant Glioma Patients Pulsed with RNA
Phase: Pilot / Feasibility
Sponsor: PI initiated
Principal Investigator: Gerald Archer
Contact: Robert Preston Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00009403

Primary and Recurrent Glioma Registry (PRoGREss)
Phase: N/A
Sponsor: PI initiated
Principal Investigator: Annick Desjardins
Contact: Brain Tumor Center at Duke
Phone: 919.684.5301
Reference Number: 00027120

Dose-finding and Safety Study of PVSRIPO Against Recurrent WHO Grade IV Malignant Glioma
Phase: Phase I
Sponsor: PI initiated
Principal Investigator: Dina Randazzo
Contact: The Preston Robert Tisch Brain Tumor Center at Duke
Phone: 919.684.5301
Reference Number: 00031169
View this trial at ClinicalTrials.gov

A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination with Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients receiving a Temozolomide Based Regimen
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Mary Affronti
Contact: Robert Preston Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00031206
View this trial at ClinicalTrials.gov

PERFORMANCE: Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Phase: Phase I
Sponsor: PI initiated
Principal Investigator: Dina Randazzo
Contact: Robert Preston Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00034208
View this trial at ClinicalTrials.gov

Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally via Convection-Enhanced Delivery for Adult Patients with Recurrent Malignant Glioma
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Dina Randazzo
Contact: Preston Robert Tisch Cancer Research Center
Phone: 919.684.5301
Reference Number: 00053325
View this trial at ClinicalTrials.gov

Evaluation of overcoming Limited migration and Enhancing cytomegalovirus-specific dendritic cell Vaccines with Adjuvant TEtanus pre-conditioning in patients with newly-diagnosed glioblastoma
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Dina Randazzo
Contact: Robert Preston Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00054740
View this trial at ClinicalTrials.gov

RESIST: Patients with IDH1 Positive Recurrent Grade II Glioma Enrolled in a Phase I Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Katherine Peters
Contact: Preston Robert Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00054746
View this trial at ClinicalTrials.gov

A Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients with Primary Glial Brain Tumors
Phase: Phase IV
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Katherine Peters
Contact: Preston Robert Tisch Cancer Research Center
Phone: 919.684.5301
Reference Number: 00055609
View this trial at ClinicalTrials.gov

A Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-naive Subjects with WHO Grade IV Malignant Glioma Followed by a Phase 2 Trial of Single Agent Marizomib.
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Annick Desjardins
Contact: Preston Robert Tisch Cancer Research Center
Phone: 919.684.5301
Reference Number: 00059540
View this trial at ClinicalTrials.gov

A Phase 1/2 Trial for Patients with Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001 (BioMimetix study # BMX-HGG-001)
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Katherine Peters
Contact: Robert Preston Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00062660
View this trial at ClinicalTrials.gov

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Katherine Peters
Contact: Preston Robert Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00063389
View this trial at ClinicalTrials.gov

Phase 2 Study of Sym004 for Adult Patients with Recurrent Glioblastoma
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Annick Desjardins
Contact: Preston Robert Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00063483
View this trial at ClinicalTrials.gov

Anti-PD-1 monoclonal antibody (nivolumab) in combination with DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Katherine Peters
Contact: Robert Preston Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00065241
View this trial at ClinicalTrials.gov

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor 06-methylguanine DNA methyltranferase) Glioblastoma (BMS CA209-548)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Katherine Peters
Contact: Preston Robert Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00071737
View this trial at ClinicalTrials.gov

A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06840003 IN PATIENTS WITH MALIGNANT GLIOMAS
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Gordana Vlahovic
Contact: Robert Preston Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00073139
View this trial at ClinicalTrials.gov

Phase 1b, Multicenter, Open-label Study of Marizomib Combined with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma. (Triphase MRZ-112)
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Annick Desjardins
Contact: Robert Preston Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00076670
View this trial at ClinicalTrials.gov

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Annick Desjardins
Contact: Preston Robert Tisch Brain Tumor Center
Phone: 919.684.5301
Reference Number: 00076758
View this trial at ClinicalTrials.gov